The new pain product combines the effects of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen, in a unique strength previously not available. The product is expected to launch during the Q2 2008, and will be promoted to primary care practitioners and dentists.
Philip Pesin, CEO of Auriga, said: “This Agreement solidifies Auriga’s commitment to enhance our product portfolio with products approved using the ANDA and 505(b)(2) NDA regulatory pathways.”